AFP reports that 2,250 people from different countries – from Great Britain, South Africa, Brazil and Poland – will be recruited for the second and third phases of the tests. The vaccine uses a “vector” (adenovirus) technology that is used to Vaccines Against Covid-19 around the world.
“Testing boosters for existing vaccines and new variants is important to ensure we are well prepared for the coronavirus pandemic,” said Andrew Pollard, director of the Oxford Vaccine Group.
Data from clinical trials will be submitted to vaccine availability regulators for evaluation in an accelerated process. If the vaccine is approved, it will be the first vaccine to be used against a specific type of coronavirus.
In May, the British government announced that clinical trials had begun to investigate the body’s immune response to the third dose of the Covid-19 vaccine due to an increase in infections with the Delta type of coronavirus.
Coronavirus: All updated information and recommendations on gov.pl.